Tradestie Institutional Equity Comparison Engine · Market Close Apr 24, 2026

AVDL vs FOLD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVDL Captures Overall Composite Edge (62.9 BUY vs 59.4 HOLD), While FOLD Leads 4–2 on Growth & Valuation Pillars

AVDL Overall Winner 6-Pillar Tally: AVDL 2 – 4 FOLD Matrix Metrics: AVDL 5 – 5 FOLD

As of Apr 24, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Amicus Therapeutics, Inc (FOLD) on higher Unified Composite conviction (62.9/100 BUY vs. 59.4/100 HOLD) after splitting the core matrix 5–5 (led by Growth & Scale, Profitability & Quality), while FOLD wins 4–2 across the 6-pillar growth and valuation breakdown. AVDL trades at $21.64 (28.8x Forward P/E, 2.5% operating margin) versus FOLD at $14.49 (17.7x Forward P/E, 8.6% operating margin).

  • Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. FOLD 59.4/100 HOLD) and 0.14β · 2% Vol risk profile, whereas FOLD leads top-line expansion (+23.7% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AVDL vs FOLD
AVDL NASDAQ Head-to-Head Winner
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
TTM Revenue $249M
Forward P/E 28.8x
Beta / 30D Vol 0.14β · 2% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50
FOLD NASDAQ
Amicus Therapeutics, Inc
Pharmaceutical Preparations
$14.49
+0.21% 1D
Market Cap $4.5B
TTM Revenue $634M
Forward P/E 17.7x
Beta / 30D Vol 0.27β · 2% Vol
Unified Composite Score
59.4 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 71.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 70
RSI-14: 70.4 · SMA20: $14.46 · SMA50: $14.40

6-Pillar Scorecard Institutional Category Breakdown (AVDL 2 – 4 FOLD)

Columns: Metric · AVDL · FOLD
1. Valuation Multiples FOLD
Forward P/E 28.8x 17.7x
Trailing P/E 16.8x 30.5x
PEG Ratio 0.07x N/M
EV / Revenue 8.5x 7.2x
2. Growth & Scale AVDL
Revenue Growth (YoY) +54.9% +23.7%
Earnings Growth (YoY) +0.0% -95.5%
TTM Revenue (USD) $249M $634M
Market Cap $2.1B $4.5B
3. Profitability & Quality AVDL
Gross Margin 94.9% 88.5%
Operating Margin 2.5% 8.6%
Net Profit Margin -0.1% -4.3%
Return on Equity (ROE) -0.3% -11.6%
4. Balance Sheet & Cash Flow FOLD
Cash Generation (TTM) $2.7M EBITDA $42M EBITDA
Cash Flow Margin 1.1% EBITDA Mgn 6.6% EBITDA Mgn
Net Cash / Leverage $1.01 Book/Sh · -0.3% ROE $0.88 Book/Sh · -11.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning FOLD
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 2.4% (<1st %ile) 0.2% (<1st %ile)
Put/Call OI Skew N/A 0.03x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat FOLD
OpEx & R&D Intensity N/A 79.9% of Rev ($507M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AVDL (5) vs FOLD (5)
Institutional Metric AVDL FOLD Criterion Row Edge
Market Capitalization
Scale
$2.1B $4.5B Larger Scale FOLD
Trailing P/E Ratio
Valuation
16.8x 30.5x Lower Multiple AVDL
Forward P/E Ratio
Valuation
28.8x 17.7x Lower Multiple FOLD
Revenue Growth (YoY)
Growth
+54.9% +23.7% Higher Growth AVDL
Operating Margin (TTM)
Profitability
2.5% 8.6% Higher Margin FOLD
Net Profit Margin
Profitability
-0.1% -4.3% Higher Margin AVDL
Return on Equity (ROE)
Capital Efficiency
-0.3% -11.6% Higher ROE AVDL
52-Week Range Position
Momentum
89% ($6–$24) 100% ($6–$14) Stronger Trend FOLD
Beta / 30D Volatility
Risk Regime
0.14β · 2% Vol 0.27β · 2% Vol Lower Realized Risk FOLD
Unified Institutional Score
Composite Signal
62.9 / 100 (BUY) 59.4 / 100 (HOLD) Higher Composite AVDL
Trailing 12M Revenue (USD)
Operating Scale
$249M $634M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
94.9% 88.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.07x PEG · 8.5x EV/Rev N/M PEG · 7.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE) $42M EBITDA ($0.88 Book/Sh · -11.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AVDL +0.44 pp
AVDL: +0.65% · FOLD: +0.21%
3M Horizon FOLD +43.28 pp
AVDL: +15.72% · FOLD: +59.0%
6M Horizon FOLD +43.52 pp
AVDL: +61.49% · FOLD: +105.01%
1Y Horizon AVDL +58.86 pp
AVDL: +160.41% · FOLD: +101.55%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVDL vs FOLD. Trailing 12-month operating profitability (AVDL 2.5% vs FOLD 8.6%) and valuation multiples (AVDL 28.8x vs FOLD 17.7x Forward P/E) are benchmarked directly in Pillar 4 below.

AVDL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$249M
Gross Margin94.9%
Op. Margin2.5%
ROE / Fwd P/E-0.3% · 28.8x
FOLD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$634M
Gross Margin88.5%
Op. Margin8.6%
ROE / Fwd P/E-11.6% · 17.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AVDL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 2.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVDL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FOLD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.2%
IV Percentile <1st %ile
Put/Call OI Skew 0.03x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact FOLD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AVDL Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FOLD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.5B market capitalization and 8.6% operating margin.
OpEx & R&D Reinvestment 79.9% of Rev ($507M)
90D Engineering Disclosures 0 Published

Investor FAQ AVDL vs FOLD Key Questions & Quantitative Answers

As of Apr 24, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Amicus Therapeutics, Inc (FOLD) on higher Unified Composite conviction (62.9/100 BUY vs. 59.4/100 HOLD) after splitting the core matrix 5–5 (led by Growth & Scale, Profitability & Quality), while FOLD wins 4–2 across the 6-pillar growth and valuation breakdown. AVDL trades at $21.64 (28.8x Forward P/E, 2.5% operating margin) versus FOLD at $14.49 (17.7x Forward P/E, 8.6% operating margin). Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. FOLD 59.4/100 HOLD) and 0.14β · 2% Vol risk profile, whereas FOLD leads top-line expansion (+23.7% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

AVDL leads the Growth & Scale pillar: AVDL posts +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin), compared with FOLD at +23.7% YoY revenue growth and -95.5% YoY earnings growth on $634M TTM revenue (88.5% gross margin, 8.6% operating margin). On trailing 12-month operating scale, AVDL generates $249M in USD-normalized revenue versus $634M for FOLD. In operating R&D and SG&A reinvestment, AVDL deploys N/A (0 90-day corporate R&D disclosures) versus 79.9% of Rev ($507M) (0 disclosures) for FOLD.

FOLD screens cheaper on headline valuation multiples. AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin), whereas FOLD trades at 17.7x Forward P/E, 30.5x Trailing P/E, N/M PEG, and 7.2x EV/Revenue (6.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVDL (-0.3% ROE) versus FOLD (-11.6% ROE) capital efficiency.

In options market volatility and institutional positioning, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk). By comparison, FOLD carries 0.2% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.03x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.27β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Apr 24, 2026. For educational research only; not investment advice.